Allogeneic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Blood Cancers, CAR-T, Gene Therapy, Non-malignant Disease, Solid Tumors
Conditions
Keywords
Data Collection, CIBMTR, NMDP, Stem Cell Transplantation, Gene Therapy, CAR-T
Brief summary
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: * Determine how well recipients recover from their transplants or cellular therapy; * Determine how recovery after a transplant or cellular therapy can be improved; * Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; * Determine how access to transplant or cellular therapy for different groups of patients can be improved; * Determine how well donors recover from the collection procedures.
Interventions
None listed
Sponsors
Center for International Blood and Marrow Transplant Research
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Eligibility to Participate in the Research Database Recipient Eligibility Criteria: * Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Individual with Marrow Toxic Injury Eligibility Criteria: * Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR. Unrelated Donor Eligibility Criteria: * All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database. * All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| A Comprehensive Source of Observational Data to assess Stem Cell Transplant | Anually - on average | A primary outcome is to have a comprehensive source of stem cell transplant data that can be used to assess topics such as: * Recipient Recover time * How recovery after transplant and other cellular therapies can be improved * Long term outcomes after transplantation and other cellular therapies * How well donors recover from collection procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| A Comprehensive Source of Data for Marrow Toxic Injuries | anually- on average | In the event of a radiation exposure accident, the NMDP has a radiation injury treatment network, whose purpose is to collect data to understand the outcomes of patients treated under these circumstances. Any patient who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Treatment Network (RITN) is eligible to participate in the Research Database. |
| Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (17-CMS-SCD) | annually - on average | This protocol supports data collection for a sub study titled 17-CMS-SCD, an observational study to compare survival of patients 15 to 50 years of age with sickle cell disease who receive allogeneic transplantation compared to those receiving standard of care treatments. * To provide a mechanism to Medicare Beneficiaries with sickle cell disease for claims coverage for allogenic hematopoietic cell transplant. * To provide data requested by Medicare under its coverage with evidence development (CED) process to make payment on claims for HCT using the existing research observational database for the CIBMTR |
| Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (10CMSMDS-1) | annually - on average | This protocol supports data collection for a sub-study titled 10-CMSMDS-1 with objective to prospectively examine outcomes of allogenic hematopoietic cell transplant in adults \>= 65 years of age with myelodysplastic syndrome to determine whether their outcomes are similar to those in younger patients. * To provide a mechanism for Medicare Beneficiaries with myelodysplastic syndrome for claims coverage for allogenic hematopoietic cell transplant * To provide data requested by Medicare under its CED to make payment on claims for HCT using the existing research observational database of the CIBMTR |
Other
| Measure | Time frame | Description |
|---|---|---|
| Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage | annually - on average | This study is the main protocol for the following two sub studies. Details for these sub-studies are found under separate NCT numbers. * Multiple Myeloma Medicare Study (NCT03127761): 17-CMS-MM * Myelofibrosis Medicare Study (NCT02934477): 16-CMS-MF |
Countries
United States
Contacts
Primary ContactLeigh Anne Blackmon
Outcome results
None listed